Raras
Buscar doenças, sintomas, genes...
Adenoma hipofisário funcional misto
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Acromegalia é um distúrbio que resulta no crescimento excessivo de certas partes do corpo humano. É causada pelo excesso de hormônio do crescimento (GH) após o fechamento das placas de crescimento. O sintoma inicial é tipicamente o aumento das mãos e dos pés. Pode também haver um aumento da testa, mandíbula e nariz. Outros sintomas podem incluir dor nas articulações, espessamento da pele, aprofundamento da voz, dores de cabeça e problemas de visão. As complicações da doença podem incluir diabetes tipo 2, apneia do sono e pressão alta.

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
8 sintomas
🦴
Ossos e articulações
8 sintomas
😀
Face
6 sintomas
🧠
Neurológico
3 sintomas
🧬
Pele e cabelo
3 sintomas
❤️
Coração
2 sintomas

+ 27 sintomas em outras categorias

Características mais comuns

Dismenorreia
Galactorreia
Fadiga
Edema palpebral
Paralisia cerebral
Disúria
60sintomas
Sem dados (60)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 60 características clínicas mais associadas, ordenadas por frequência.

DismenorreiaDysmenorrhea
GalactorreiaGalactorrhea
FadigaFatigue
Edema palpebralPalpebral edema
Paralisia cerebralCerebral palsy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos119publicações
Pico202417 papers
Linha do tempo
20202015Hoje · 2026📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Adenoma hipofisário funcional misto

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Clinical and radiological features of Rathke's cleft cysts with inflammatory change: Multivariable analysis of 262 surgically treated cases.

Clinical neurology and neurosurgery2026 Mar

To characterize clinical and MRI features of Rathke's cleft cysts (RCCs) with inflammatory change and assess their associations with endocrine and surgical outcomes. We retrospectively reviewed 262 surgically treated RCCs at a single institution (1998-2023). All patients underwent preoperative MRI and endocrine testing. Postoperative pathology classified cases as with inflammatory change (Group A, n = 56) or without (Group B, n = 206). Group comparisons used standard statistics; key MRI signs were circumferential rim enhancement and mixed T2 signal. Compared with Group B, Group A had more impaired pituitary axes (mean 3.9 vs. 1.1; p < 0.001) and higher rates of diabetes insipidus (33.9 % vs. 1.5 %; p < 0.0001) and visual field defects (62.5 % vs. 31.6 %; p < 0.0001). Circumferential rim enhancement (71.4 % vs. 6.3 %; p < 0.0001) and mixed T2 signal (66.1 % vs. 6.8 %; p < 0.0001) were strongly associated with inflammatory change. Postoperative endocrine recovery was less frequent in Group A (21.7 % vs. 64.6 %; p < 0.0001), and reoperation for recurrence was more common (14.3 % vs. 2.4 %; p = 0.001). Two illustrative cases demonstrated concordance between inflammation severity, MRI features, and outcomes. RCCs with inflammatory change are associated with severe preoperative pituitary dysfunction, poorer endocrine recovery, and higher recurrence. Simple MRI signs-especially circumferential rim enhancement and mixed T2 signal-may help identify inflammatory cases preoperatively and support consideration of earlier surgical intervention to preserve pituitary function.

#2

Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.

Current oncology (Toronto, Ont.)2026 Feb 04

Pituitary neuroendocrine tumors (PitNETs) are a core manifestation of multiple endocrine neoplasia type 1 (MEN1), yet their true prevalence, biological behavior, and optimal management remain debated. Earlier reports suggested increased aggressiveness compared with sporadic PitNETs, while more recent surveillance-based studies indicate a predominantly indolent phenotype. We conducted a retrospective single-center study including all patients with clinical, familial, or genetic MEN1 referred to the Endocrinology Unit of the University of Naples "Federico II", ENETS Center of Excellence, between January 2004 and June 2025. Demographic, clinical, radiological, hormonal, and therapeutic data were systematically collected. PitNETs were classified by size and hormonal activity. Among 103 MEN1 patients (61 women), 50 (48.5%) were diagnosed with PitNETs at a mean age of 35.1 years. Microadenomas predominated (60%), and tumors were equally distributed between functioning and non-functioning lesions. Prolactin-secreting PitNETs were the most common functioning subtype (42%), followed by rare GH-, ACTH-, or mixed-secreting PitNETs. Dopamine agonists, mainly cabergoline, were prescribed in 38% of cases, while neurosurgical intervention was required in 14%, exclusively for macroadenomas. During follow-up, recurrence occurred in 8% of patients. No significant sex-related differences were observed in prevalence, tumor size, functional status, treatment approach, or outcomes. In our MEN1 cohort, PitNETs were frequent but largely indolent, with a predominance of microadenomas and limited need for surgery. Our findings support individualized, subtype-driven surveillance strategies, with conservative management for clinically non-functioning microadenomas and closer monitoring of prolactin-secreting PitNETs due to variable medical responsiveness.

#3

Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE).

Radiation oncology (London, England)2026 Feb 14

Radiation therapy (RT) plays a significant role in the multimodal management of primary brain tumors, improving oncological outcomes. However, despite advances such as Intensity-Modulated Radiation Therapy (IMRT), photon-based RT inevitably exposes normal organs to low-dose radiation, leading to long-term functional morbidities like cognitive decline, endocrine dysfunction, auditory toxicity. These late effects are particularly concerning in patients with favorable prognoses and protracted survival. Proton beam therapy (PBT), owing to its unique physical properties, holds promise for better functional preservation, but robust clinical data in adults are lacking. The PRIDE study is a prospective, open-label, phase 3 randomized controlled trial enrolling adults aged 18-70 years undergoing focal cranial RT with conventional fractionation for primary brain tumors with expected survival > 5 years at Tata Memorial Centre, Mumbai. Participants will be randomized 1:1 to receive either photon-IMRT (standard arm) or PBT (experimental arm), stratified by age, tumor type, proximity to the hypothalamic-pituitary axis, and radiation dose. The primary endpoint is 5-year functional survival, defined as survival without functional deterioration (neurocognitive decline, significant ototoxicity, new or worsening endocrine dysfunction, neurological impairment, severe radio-necrosis, disease progression, or death). Secondary endpoints include patient-reported quality of life and health economic analysis. Survival outcomes will be analyzed using Kaplan-Meier methods with log-rank test. Neurocognitive and quality-of-life data will be evaluated using linear mixed-effects and non-parametric tests. A total of 156 patients will be enrolled, accounting for 20% attrition, to detect a 25% absolute improvement in 5-year functional survival favoring PBT (65% vs 40%, HR 0.47, α=0.05, power=80%). An interim analysis has been planned using the O'Brien-Fleming rule after 50% of the events (n=28). This trial will provide level 1 evidence investigating the role of PBT in functional outcomes among adults with primary brain tumors. If study endpoint is achieved, PBT will be considered as standard of care guiding contemporary neuro-oncology practice. The trial has been approved by the Institutional Ethics Committee of Tata Memorial Centre, Mumbai. The trial has been registered with the Clinical Trial Registry of India (CTRI/2025/03/082568) and Clinicaltrials.gov (study identifier NCT06831461).

#4

Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients.

Acta neuropathologica communications2026 Jan 30

The vast majority of tumours in the sellar region are pituitary neuroendocrine tumours, also called pituitary adenomas. Sellar gangliocytomas (GCs), benign tumours that originate from neuronal ganglionic cells, account for less than 1% of sellar tumours. Even rarer are mixed gangliocytoma-pituitary neuroendocrine tumours (GC-PitNET). These tumours are often associated with hormone hypersecretion, most commonly resulting in acromegaly. The histogenesis of mixed GC-PitNET is currently unclear. In this paper, we present comprehensive clinical, immunohistochemical, targeting enrichment next generation DNA sequencing, and genome-wide methylation data from four patients with mixed GC-PitNETs, three with acromegaly and one with Cushing's disease. Transcriptomic data are also included for two of the patients. Our findings indicate that mixed GC-PitNETs have different clinical course, with the acromegaly patients showing greater resistance to pharmacological therapy, as well as different protein expression and molecular features compared to respective pure PitNETs. The transcriptomic data on two patients with somatotroph GC-PitNET show involvement of mitochondrial and ribosomal genes, suggesting a distinct gene expression pattern, in comparison with pure somatotroph tumours. Furthermore, the expression pattern of selected stem cell markers, mainly SOX9, supports a common origin of the neuroendocrine and ganglionic tumour components, suggesting the involvement of stem cells in tumorigenesis.

#5

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.

Endocrine oncology (Bristol, England)2026 Jan

Functional pituitary tumours, also called pituitary neuroendocrine tumours (PitNETs), typically produce a single hormone, based on the cell lineage from which they arise in the anterior pituitary. Pituitary adenoma dual hypersecretion is less common and may present management dilemmas. Prolactin (PRL) and growth hormone (GH) co-secreting pituitary adenomas (GH and PRL-PA) are the most common form of pituitary adenoma dual hypersecretion, arising from PIT1-lineage PitNETs, most commonly mammosomatotroph and mixed somatotroph-lactotroph adenomas. Pharmacotherapies employed in prolactinoma (i.e. dopamine agonists) and acromegaly (e.g. somatostatin analogues) may be used in GH and PRL-PA, in addition to transsphenoidal surgery. However, the ideal treatment of this rare PA subtype is unknown, reflected by a lack of specific treatment recommendations in both acromegaly and prolactinoma guidelines. Herein, we present an individual with a giant GH and PRL-PA with complete biochemical (GH and PRL), and partial structural, ophthalmological and clinical, responses to upfront cabergoline monotherapy. This case, along with previous data showing GH and structural responses to cabergoline in individuals with acromegaly and hyperprolactinaemia, argue for a role for cabergoline monotherapy in the treatment armamentarium of GH and PRL-PAs, noting that some tumours may exhibit a significant treatment response as observed here. GH and PRL-PA is a typically aggressive form of pituitary adenoma.Cabergoline monotherapy can be an effective treatment option for select case of GH and PRL-PA, resulting in both biochemical and structural responses.Some GH and PRL-PAs may exhibit a 'hyper-response' to cabergoline with rapid, profound hormone reduction and/or tumour shrinkage.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 119

2026

Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.

Current oncology (Toronto, Ont.)
2026

Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE).

Radiation oncology (London, England)
2026

Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients.

Acta neuropathologica communications
2026

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.

Endocrine oncology (Bristol, England)
2026

Clinical and radiological features of Rathke's cleft cysts with inflammatory change: Multivariable analysis of 262 surgically treated cases.

Clinical neurology and neurosurgery
2025

Brain injury biomarkers and intraoperative hypotension: associations with pituitary hormone deficiency following transsphenoidal endoscopic surgery for non-functioning pituitary adenomas.

Pituitary
2025

Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis.

Frontiers in endocrinology
2025

Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment.

European journal of endocrinology
2025

Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors.

Scientific reports
2026

Comprehensive Comparison of Visual Outcomes in Macro and Giant Prolactinoma Cohorts Managed With Medical Versus Surgical Treatment.

Neurosurgery
2025

Epidemiologic Profile and Clinical Outcomes of Adult Patients with Prolactinoma at the Philippine General Hospital.

Acta medica Philippina
2025

Minimally Invasive Cyst Drainage for Cystic Craniopharyngioma: Neuroendoscopic Fenestration or Stereotactic Cyst Drainage?

World neurosurgery
2025

Endoscopic endonasal surgery using indocyanine green fluorescence endoscope for Cushing's disease caused by mixed intrasellar gangliocytoma and adrenocorticotropin adenoma: illustrative case.

Journal of neurosurgery. Case lessons
2026

Integrative Machine Learning Approach for Predicting Resistance to First-generation Receptor Ligands in Acromegaly.

The Journal of clinical endocrinology and metabolism
2025

Prevalence, risk factors, and impacts of sleep disturbances in patients with primary brain tumors: a systematic review.

Neurosurgical review
2025

Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant.

Endocrine
2025

The oxytocin system in patients with craniopharyngioma: A systematic review.

Frontiers in neuroendocrinology
2024

Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective.

Frontiers of hormone research
2024

GH-Secreting Adenoma or Tumor? Issues in Pituitary Neoplasms Nomenclature, Classification, and Characterization.

Frontiers of hormone research
2025

Mixed Gangliocytoma-Pituitary Adenoma: A Systematic Review of Diagnostic Features, Clinical Management, and Surgical Outcomes.

World neurosurgery
2024

B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance.

Endocrinology
2025

Deleterious effects of social isolation on neuroendocrine-immune status, and cancer progression in rats.

Brain, behavior, and immunity
2024

A multicenter study of clinical outcomes and volumetric trends in suspected microprolactinomas.

Neurosurgical review
2024

[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls].

Problemy endokrinologii
2024

Genome-Wide DNA Methylation Profiling as a Prognostic Marker in Pituitary Adenomas-A Pilot Study.

Cancers
2024

Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.

Journal of neuropathology and experimental neurology
2024

Shaping the curve from the microscopic transsphenoidal to the endoscopic endonasal approach for the sellar region.

Cirugia y cirujanos
2024

Endoscopic endonasal transsphenoidal approach improves endocrine function and surgical outcome in primary craniopharyngioma resection: a systematic review and meta-analysis.

World journal of surgical oncology
2024

Complete Shrinking of Mixed Growth Hormone and Prolactin-Secreting Pituitary Adenoma With Bromocriptine Therapy Alone.

The Journal of craniofacial surgery
2024

Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2024

The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism.

Endocrine reviews
2024

Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2024

Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy.

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2024

Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases.

The Journal of clinical endocrinology and metabolism
2024

Clinical Characteristics of Childhood-Onset Craniopharyngioma.

Alternative therapies in health and medicine
2024

Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience.

Endocrinology and metabolism (Seoul, Korea)
2023

PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas.

Frontiers in endocrinology
2023

The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.

International journal of molecular sciences
2023

Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.

International journal of molecular sciences
2023

Determination of PDK1, SLC2A1, EGFR, PTEN, CD276 Gene Expression Levels and IDH1 Gene R132H Polymorphism in Brain Tumor Tissues.

Turkish neurosurgery
2023

Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion.

Frontiers in endocrinology
2023

Altered hemispheric asymmetry of attentional networks in patients with pituitary adenoma: an event-related potential study.

Frontiers in neuroscience
2023

Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.

Pituitary
2023

Social determinants of cognitive outcomes in survivors of pediatric brain tumors treated with conformal radiation therapy.

Neuro-oncology
2023

Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only.

Journal of neurosurgery. Pediatrics
2022

A rare pituitary tumor associated with hyperthyroidism and acromegaly.

Frontiers in endocrinology
2022

[New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].

Zhonghua yi xue za zhi
2022

Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.

Cells
2023

Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy.

Endocrine-related cancer
2022

Aspirin Mediates Its Antitumoral Effect Through Inhibiting PTTG1 in Pituitary Adenoma.

The Journal of clinical endocrinology and metabolism
2022

Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.

Frontiers in endocrinology
2022

Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation.

Frontiers in endocrinology
2022

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Endocrine pathology
2022

Osilodrostat oral tablets for adults with Cushing's disease.

Expert review of endocrinology &amp; metabolism
2022

Mixed gangliocytoma-pituitary adenoma in MEN1 syndrome: A case report and literature review.

Neuropathology : official journal of the Japanese Society of Neuropathology
2022

Equivalent outcomes in nasal symptoms following microscopic or endoscopic transsphenoidal surgery: results from multi-centre, prospective study.

Acta neurochirurgica
2022

Gamma knife radiosurgery in pituitary adenomas. A single-center experience.

Medicina
2022

Novel Classification of Acromegaly in Accordance with Immunohistochemical Subtypes: Is There Really a Clinical Relevance?

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2021

Endocrine Disrupting Chemicals and Reproductive Health in Boys and Men.

Frontiers in endocrinology
2021

Sleep disturbances in craniopharyngioma: a challenging diagnosis.

Journal of neurology
2021

Multiple roles for peptidylglycine α-amidating monooxygenase in the response to hypoxia.

Journal of cellular physiology
2021

Altered endocannabinoid-dynamics in craniopharyngioma patients and their association with HPA-axis disturbances.

European journal of endocrinology
2021

A Potential Concomitant Sellar Embryonic Remnant-Associated Collision Tumor: Systematic Review.

Frontiers in oncology
2021

PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.

Endocrine pathology
2021

The impact of socioeconomic status (SES) on cognitive outcomes following radiotherapy for pediatric brain tumors: a prospective, longitudinal trial.

Neuro-oncology
2021

Primary intrasellar schwannoma with intratumoral hemorrhage mimicking pituitary apoplexy: A case report.

Neuro-Chirurgie
2021

Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain.

Neuroendocrinology
2020

Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly.

Pituitary
2022

Pediatric pituitary adenoma with mixed FSH and TSH immunostaining and FSH hypersecretion in a 6 year-old girl with precocious puberty: case report and multidisciplinary management.

The International journal of neuroscience
2020

Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region".

The Journal of clinical endocrinology and metabolism
2020

Mixed Sparsely Granulated Lactotroph and Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor Expands the Spectrum of Neuroendocrine Neoplasms in Ovarian Teratomas: the Role of Pituitary Neuroendocrine Cell Lineage Biomarkers.

Endocrine pathology
2020

Prior smoking and nasoseptal flap usage adversely impact quality of life and healing after endoscopic pituitary surgery.

Neurosurgical focus
2020

Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF-1-positive sellar lesions.

Neuropathology and applied neurobiology
2020

Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test.

Thyroid : official journal of the American Thyroid Association
2020

Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome.

Clinical neurology and neurosurgery
2020

Patients with true mixed growth hormone and prolactin-secreting pituitary adenoma: a case series of 12 patients.

British journal of neurosurgery
2020

10 Years' Experience of Using Low-Field Intraoperative MRI in Transsphenoidal Surgery for Pituitary Adenoma: Results of the Swiss Pituitary Registry (SwissPit).

World neurosurgery
2019

A Novel, Hybrid, Stereotactic Approach (Radiosurgery and Dual Ommaya Reservoirs) for the Treatment of Mixed (Polycystic and Solid) Craniopharyngioma.

Stereotactic and functional neurosurgery
2019

Functioning Pituitary Adenoma with Xanthogranulomatous Features: Review of Literature and Case Report.

Journal of neurological surgery. Part B, Skull base
2019

Sellar/Suprasellar Ganglioglioma: Clinical Image.

World neurosurgery
2019

Comprehensive Evaluation of Rare Pituitary Lesions: A Single Tertiary Care Pituitary Center Experience and Review of the Literature.

Endocrine pathology
2019

Prediction of calcification tendency in pediatric cystic adamantinomatous craniopharyngioma by using inflammatory markers, hormone markers, and radiological appearances.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2019

Primary tumors of the posterior pituitary: A systematic review.

Reviews in endocrine &amp; metabolic disorders
2019

Ex Vivo 1H NMR study of pituitary adenomas to differentiate various immunohistochemical subtypes.

Scientific reports
2019

PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2018

Pediatric pituitary adenomas in Northeast Mexico. A follow-up study.

Endocrine
2018

Predicting parental distress among children newly diagnosed with craniopharyngioma.

Pediatric blood &amp; cancer
2018

Pituitary adenomas in children and young adults.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2018

Epidemiology and biomarker profile of pituitary adenohypophysial tumors.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2018

A prospective longitudinal study of Pasireotide in Nelson's syndrome.

Pituitary
2018

Silent somatotroph pituitary adenomas: an update.

Pituitary
2018

HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Cell cycle (Georgetown, Tex.)
2017

Editor's Highlight: Structure-Based Investigation on the Binding and Activation of Typical Pesticides With Thyroid Receptor.

Toxicological sciences : an official journal of the Society of Toxicology
2017

Unusual presentations of Carney Complex in patient with a novel PRKAR1A mutation.

Neuro endocrinology letters
2017

Adrenal Cushing's syndrome during pregnancy.

European journal of endocrinology
2017

An FSH and TSH pituitary adenoma, presenting with precocious puberty and central hyperthyroidism.

Endocrinology, diabetes &amp; metabolism case reports
2017

X-LAG: How did they grow so tall?

Annales d'endocrinologie
2017

Epigenetic Pathways in Human Disease: The Impact of DNA Methylation on Stress-Related Pathogenesis and Current Challenges in Biomarker Development.

EBioMedicine
2017

High Ki-67 expression is associated with prolactin secreting pituitary adenomas.

Bosnian journal of basic medical sciences
2016

Screening for genetic causes of growth hormone hypersecretion.

Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2016

A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.

The Tokai journal of experimental and clinical medicine
2016

Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas.

Molecular and cellular endocrinology
2016

TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.

Oncotarget
2016

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

Endocrine-related cancer
2016

Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells.

Oncology reports
2016

Three-dimensional Alginate-bead Culture of Human Pituitary Adenoma Cells.

Journal of visualized experiments : JoVE
2016

[Misleading diagnosis of hyperprolactinemia in women].

Gynecologie, obstetrique &amp; fertilite
2016

Unicystic Ameloblastomatoid Cystic Craniopharyngioma: Pathological Discussion and Clinical Significance of Cyst Formation in Adamantinomatous Craniopharyngioma.

Pediatric neurosurgery
2016

GHRH excess and blockade in X-LAG syndrome.

Endocrine-related cancer
2016

Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.

Endocrine
2016

Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
2016

GHRH Receptor Expression in Malignant Mixed Müllerian Tumors: A Potentially Targetable Biopredictor.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
2015

Ganglion cell tumours in the sella turcica in close morphological connection with pituitary adenomas.

Folia neuropathologica
2016

Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Endocrine pathology
2016

Sellar gangliocytoma with adrenocorticotropic and prolactin adenoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2015

Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.

Thyroid : official journal of the American Thyroid Association
2015

Neuropsychiatric and cardiometabolic comorbidities in patients with previously diagnosed Cushing's disease: a longitudinal observational study.

BMJ open
2015

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas.

European journal of endocrinology
2015

A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.

Clinical pharmacokinetics

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Adenoma hipofisário funcional misto.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Adenoma hipofisário funcional misto

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Clinical and radiological features of Rathke's cleft cysts with inflammatory change: Multivariable analysis of 262 surgically treated cases.
    Clinical neurology and neurosurgery· 2026· PMID 41506125mais citado
  2. Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.
    Current oncology (Toronto, Ont.)· 2026· PMID 41744861mais citado
  3. Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE).
    Radiation oncology (London, England)· 2026· PMID 41689093mais citado
  4. Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients.
    Acta neuropathologica communications· 2026· PMID 41618392mais citado
  5. Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.
    Endocrine oncology (Bristol, England)· 2026· PMID 41532055mais citado
  6. Brain injury biomarkers and intraoperative hypotension: associations with pituitary hormone deficiency following transsphenoidal endoscopic surgery for non-functioning pituitary adenomas.
    Pituitary· 2025· PMID 41359198recente
  7. Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment.
    Eur J Endocrinol· 2025· PMID 41140065recente
  8. Comprehensive Comparison of Visual Outcomes in Macro and Giant Prolactinoma Cohorts Managed With Medical Versus Surgical Treatment.
    Neurosurgery· 2026· PMID 40767496recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:314759(Orphanet)
  2. MONDO:0017822(MONDO)
  3. GARD:21390(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q55787418(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Adenoma hipofisário funcional misto
Compêndio · Raras BR

Adenoma hipofisário funcional misto

ORPHA:314759 · MONDO:0017822
MedGen
UMLS
C0346305
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades